Engineered immune cells take on Hard-to-Treat KRAS cancers
NCT ID NCT07342738
First seen Jan 15, 2026 · Last updated Apr 28, 2026 · Updated 12 times
Summary
This early-phase study tests a personalized cell therapy (TCR-T) in 25 adults with advanced solid tumors caused by KRAS mutations, such as certain colorectal and lung cancers. The treatment involves collecting the patient's own immune cells, engineering them to better recognize and attack cancer, then infusing them back. The main goals are to check safety and see if tumors shrink or stabilize.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.